Table 3. . Patient characteristics.
| Study (year) | Co-morbidities (ICU vs non-ICU) |
SAR-CoV-2 diagnosis | Symptoms | Complications (ICU vs non-ICU) |
Treatments (ICU vs non-ICU) |
|---|---|---|---|---|---|
| Aminian et al. (2020) | Obesity: n = 1 (33.3%) | Lab confirmation done by quantitative RT-PCR on samples from nasopharynx | Abdo pain: (n = 1; 33.3%) Diarrhea: (n = 1; 33.3%) Dry cough: (n = 1; 33.3%) Dyspnea: (n = 3; 100%) Fever: (n = 3; 100%) Vomiting: (n = 1; 33.3%) |
ARDS: n = 2 (66.6%) ACI: n = 1 (33.3%) |
NS |
|
Cai et al. (2020) |
Smoking: (n = 4; 57.1%) COPD: (n = 2; 28.6%) CVD: (n = 3; 32.4%) ILD: (n = 1; 14.3%) |
Lab confirmation done by quantitative RT-PCR on samples from respiratory tract Time of surgery to first symptom: (IQR; median) 7.0 (7.0–10.0) days |
Diarrhea: (n = 1; 14.3%) Dry cough: (n = 4; 57.1%) Dyspnea: (n = 5; 71.4%) Fever: (n = 7; 100%) Fatigue: (n = 2; 28.6%) Myalgia: (n = 2; 28.6%) Palpitation: (n = 1; 14.3%) |
NS | Antivirals/antibiotics n = 7 (100%) Corticosteroids n = 4 (57.1%) IMV n = 3 (32.4%) Immunoglobulins n = 3 (42.9%) Oxygen n = 7 (100%) |
|
Lei et al. (2020) |
Any: n = 20 (58.8%) (80 vs 42.1%; p = 0.04) HTN: n = 13 (38.2%) (60 vs 21.1%; p = 0.03) CVD: n = 7 (20.6%) (40 vs 5.3%; p = 0.03) Other (p > 0.05, NS): Malignancy: n = 9 (26.5%) Diabetes: n = 8 (23.5%) CBD: n = 2 (5.9%) COPD: n = 1 (2.9%) CKD: n = 1 (2.9%) Moderate-/high-risk surgery: n = 22 (64.7%) (93.4 vs 42.1%; p < 0.05) |
Lab confirmation done by quantitative RT-PCR on samples from respiratory tract Time of surgery to first symptom: (IQR; median) 2.0 (1.0–4.0) days First symptom to dyspnea: (IQR; median) 3.5 (2.0–5.3) days |
Five most common: Dry cough: (n = 18; 53%) Dyspnea: (n = 15; 44.1%) Fatigue: (n = 25; 74%) Fever: (n = 31; 91%) Myalgia: (n = 11; 32.4%) No significant difference between ICU and non-ICU patients |
ARDS: n = 11 (32.4%) (60 vs 10.5%; p = 0.003) Shock: n = 10 (29.4%) (53.3 vs 10.5%; p = 0.01) 20 infection: n = 10 (29.4%) (46.7 vs 10.5%; p = 0.01) ACI: n = 5 (14.7%) (33.3 vs 0%; p = 0.01) Other (p > 0.05, NS): Arrhythmia: n = 8 (23.5%) AKI: n = 2 (5.9%) |
Antivirals/antibiotics n = 34 (100%) Glucocorticoids n = 16 (47.1%) Immunoglobulins n = 14 (41.2%) CKRT n = 1 (2.9%) Oxygen n = 19 (55.9%) NIV n = 10 (29.4%) IMV n = 5 (14.7%) ECMO n = 1 (2.9%) |
|
Li et al. (2020) |
Smoking: n = 7 (53.8%) HTN: n = 2 (15.4%) Diabetes: n = 1 (7.7%) COPD: n = 5 (38.5%) CHD: n = 4 (30.8%) |
Lab confirmation by quantitative RT-PCR on samples from respiratory tract Days of exposure to onset of fever: 5.9 ± 4.7 days |
Cough: n = 10 (76.9%) Diarrhea: n = 2 (15.4%) Dyspnea: n = 12 (92.3%) Fatigue: n = 8 (61.5%) Fever: n = 13 (100.0%) |
NS | NS |
|
Panciani et al. (2020) |
NS | Lab confirmation by quantitative RT-PCR on samples from nasopharynx | NS | Thrombocytopenia: n = 2 (40%) Interstitial pneumonia: n = 5 (100%) |
Antivirals/antibiotics n = 5 (100%) Hydroxychloroquine n = 5 (100%) |
|
Yang et al. (2020) |
Diabetes: n = 2 (66.7%) HTN: n = 3 (100%) |
Lab confirmation by quantitative RT-PCR on samples from throat Days of exposure to onset of fever: 6 days Time of surgery to first symptom: 1.3 days |
Cough: n = 1 (33.3%) Dyspnea: n = 0 (0%) Fever: n = 3 (100.0%) |
NS | Antivirals/antibiotics n = 3 (100%) |
ACI: Acute cardiac injury; AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome; CBD: Cerebrovascular disease; CHD: Coronary heart disease; CKD: Chronic kidney disease; CKRT: Continuous kidney replacement therapy; COPD: Chronic obstructive pulmonary disease; CVD: Cardiovascular disease; ECMO: Extracorporeal membrane oxygenation; HTN: Hypertension; ICU: Intensive care unit; ILD: Interstitial lung disease; IMV: Invasive mechanical ventilation; IQR: Interquartile range; NIV: Noninvasive ventilation; NS: Nonsignificant; RT-PCR: Reverse transcriptase PCR.